Surglasses promise breakthrough in mixed reality med-tech

By Harry Menear
The Taiwanese medical technology firm Taiwan Main Orthopaedics Biotechnology - which trades under the brand name Surglasses - has announced the launch o...

The Taiwanese medical technology firm Taiwan Main Orthopaedics Biotechnology - which trades under the brand name Surglasses - has announced the launch of new mixed reality medical technology that goes further towards the world of science fiction than anything in the field so far. 

Reportedly giving surgeons “a superiority rivaling any fictional character, especially the man with the X-ray eyes,” Surglasses’ latest offering is expected to do big things in the spinal navigation market. 

The augmented reality (AR) smart glasses are used to position particular entry points and they can reveal the necessary angles for the screws to be attached for a spinal surgery. Traditionally, surgeons use a technique called fluoroscopy to verify the needle insertion, requiring them to periodically look away from the patient to observe the monitor. Surglasses claims that the Caduceus surgical glasses mean that a surgeon will be able to see the exact position of the needle without ever taking their eyes off of the patient. 

The Caduceus glasses reportedly allow surgeons to see through a patient's body at a 3D model of the anatomy of the patient's vascular and nervous systems. 

SEE ALSO:

Augmented and Virtual Reality are both quickly becoming a key growth technology in the medical space, as anything that gives surgeons better information during procedures, or diagnosticians the ability to deliver expertise remotely, has powerful applications in the space. 

Alongside medical technology, mixed reality is expected to see heavy adoption in the architecture, aerospace, industrial and defense industries. In 2020, the mixed reality market is expected to be worth more than $450mn, representing a CAGR of more than 75% since 2016. In the healthcare sector, virtual reality alone is expected to generate more than $3.7bn a year by 2027. 

Caduceus is going through the final process of FDA approval and is expected to enter full-scale production in the middle of 2020. 

Share

Featured Articles

Exec Q&A: Alex Cruz-Farmer, Cisco ThousandEyes

Alex Cruz-Farmer, Principal Product Manager at Cisco ThousandEyes, explains how their technology brings new levels of visibility to hidden DX issues.

Cloud & 5G - Day 2 highlights from the in-person stage

TECH LIVE LONDON returned to the Tobacco Dock last week. Stage host and Technology Magazine Editor in Chief, Alex Tuck, breaks down the presentations

Cloud & 5G - Day 1 highlights from the in-person stage

TECH LIVE LONDON returned to the Tobacco Dock last week. The stage host and Technology Magazine Editor in Chief, Alex Tuck, discusses the key themes

TECH LIVE LONDON: Day 2 highlights of the hybrid tech show

Digital Transformation

TECH LIVE LONDON: An overview of the hybrid technology show

Digital Transformation

TECH LIVE LONDON: Begins tomorrow at 10am!

Digital Transformation